Summary:
In postmenopausal women with overweight or obesity, high-dose green tea extract (GTE) supplementation (843 ± 44 mg EGCG/day) did not significantly reduce inflammatory cytokines compared to placebo over a 12-month period, and it was not associated with notable side effects.
| PICO | Description |
|---|---|
| Population | Postmenopausal women with overweight or obesity, participating in the Minnesota Green Tea Trial (n = 97). |
| Intervention | Daily supplementation with high-dose green tea extract containing 843 ± 44 mg epigallocatechin gallate (EGCG) for 12 months. |
| Comparison | Placebo group receiving an identical capsule without active ingredients for the same duration. |
| Outcome | No statistically significant differences were observed between GTE and placebo groups for changes in serum CRP (p = 0.24), IL-6 (p = 0.59), or TNF-α (p = 0.36) over 12 months. COMT genotype did not modify these effects. |
Clinical Context
Green tea polyphenols, particularly epigallocatechin gallate (EGCG), have demonstrated anti-inflammatory properties in laboratory studies, leading to considerable interest in their potential for reducing chronic low-grade inflammation associated with obesity and metabolic disease. Postmenopausal women with excess weight represent a population at heightened risk for inflammation-related conditions including cardiovascular disease, type 2 diabetes, and certain cancers. The loss of estrogen’s anti-inflammatory effects combined with adipose tissue expansion creates a proinflammatory state characterized by elevated cytokines including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. These biomarkers serve as independent predictors of cardiovascular events and metabolic deterioration. Green tea extract supplements have been marketed for various health benefits including anti-inflammatory effects, weight management, and disease prevention. This secondary analysis from the Minnesota Green Tea Trial provides rigorous evidence on whether high-dose EGCG supplementation can meaningfully reduce systemic inflammation in a population where such effects would be particularly valuable.
Clinical Pearls
- High-dose green tea extract providing over 800 mg daily of EGCG for 12 months produced no significant reduction in C-reactive protein, interleukin-6, or tumor necrosis factor-alpha compared to placebo.
- The lack of anti-inflammatory effect was consistent across all measured cytokines, suggesting a robust null finding rather than selective inefficacy.
- Catechol-O-methyltransferase (COMT) genotype, which affects EGCG metabolism, did not modify the inflammatory response, indicating genetic variation does not explain the negative results.
- The intervention was well-tolerated with no notable side effects, confirming the safety of long-term high-dose EGCG supplementation in this population.
Practical Application
Clinicians should not recommend green tea extract supplements for anti-inflammatory purposes in postmenopausal women with overweight or obesity based on this evidence. Patients using such supplements with the expectation of reducing inflammation should be counseled about these null findings. The study does not discourage moderate green tea beverage consumption, which may offer other benefits and is part of cultural dietary patterns in many populations. For managing chronic inflammation in postmenopausal women with excess weight, evidence-based approaches including weight reduction, regular physical activity, and dietary pattern modifications such as Mediterranean diet adoption remain the cornerstones of intervention. Anti-inflammatory pharmacotherapy should follow established guidelines when clinically indicated.
Broader Evidence Context
These findings contribute to a growing body of literature questioning whether the anti-inflammatory effects of green tea polyphenols observed in vitro and in animal models translate to meaningful clinical benefits in humans. Previous smaller trials have yielded inconsistent results, with some showing modest inflammatory marker reductions and others showing no effect. The longer duration and adequate sample size of this trial provide more definitive evidence. The results align with systematic reviews suggesting that green tea supplementation has limited effects on inflammatory biomarkers. This pattern of laboratory promise failing to translate into clinical efficacy is common in nutritional supplement research.
Study Limitations
- This was a secondary analysis of a trial designed primarily for other endpoints, potentially limiting statistical power for inflammatory markers.
- The sample size of 97 participants may have been insufficient to detect modest anti-inflammatory effects that could still be clinically relevant.
- Participants were generally healthy postmenopausal women; those with established inflammatory conditions might respond differently.
- Baseline inflammatory marker levels were not markedly elevated, potentially creating a floor effect that limited observable improvement.
- Dietary habits including background tea consumption were not rigorously controlled and could confound results.
Bottom Line
High-dose green tea extract supplementation providing over 800 mg of EGCG daily for 12 months does not reduce inflammatory cytokines in postmenopausal women with overweight or obesity. Clinicians should not recommend green tea supplements for anti-inflammatory purposes in this population based on current evidence.
Source: Cunningham, Anca, et al. “Effects of Green Tea Extract Supplementation on Inflammatory Cytokines Among Postmenopausal Women with Overweight or Obesity—A Secondary Analysis of a Randomized Controlled Trial.” Read article here.
